Clinical guidelines for late-onset Pompe disease

Before 2006, Pompe disease or glycogenosis storage disease type II was an incurable disease whose treatment was merely palliative. The development of a recombinant human alpha-glucosidase enzymatic replacement therapy has become the first specific treatment for this illness. The aim of this guide is...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista de neurologiá 2012-04, Vol.54 (8), p.497-507
Hauptverfasser: Barba-Romero, M A, Barrot, E, Bautista-Lorite, J, Gutierrez-Rivas, E, Illa, I, Jimenez, L M, Ley-Martos, M, Lopez de Munain, A, Pardo, J, Pascual-Pascual, S I, Perez-Lopez, J, Solera, J, Vilchez-Padilla, J J
Format: Artikel
Sprache:eng ; spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 507
container_issue 8
container_start_page 497
container_title Revista de neurologiá
container_volume 54
creator Barba-Romero, M A
Barrot, E
Bautista-Lorite, J
Gutierrez-Rivas, E
Illa, I
Jimenez, L M
Ley-Martos, M
Lopez de Munain, A
Pardo, J
Pascual-Pascual, S I
Perez-Lopez, J
Solera, J
Vilchez-Padilla, J J
description Before 2006, Pompe disease or glycogenosis storage disease type II was an incurable disease whose treatment was merely palliative. The development of a recombinant human alpha-glucosidase enzymatic replacement therapy has become the first specific treatment for this illness. The aim of this guide is to serve as reference for the management of the late-onset Pompe disease, the type of Pompe disease that develops after one year of age. In the guide a group of Spanish experts make specific recommendations about diagnosis, follow-up and treatment of this illness. With regard to diagnosis, the dried blood spots method is essential as the first step for the diagnosis of Pompe disease. The confirmation of the diagnosis of Pompe disease must be made by means of an study of enzymatic activity in isolated lymphocytes or a mutation analysis of the alpha-glucosidase gene. With regard to treatment with enzymatic replacement therapy, the experts say that is effective improving or stabilizating the motor function and the respiratory function and it must be introduced when the first symptoms attributable to Pompe disease appear.
doi_str_mv 10.33588/rn.5408.2012088
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1015092038</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1015092038</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-59565be0f7720a701e6b60ee6a296dcf1dd7f339e25c2575b063c8f55b8d401e3</originalsourceid><addsrcrecordid>eNo1z0tLxDAUBeAgiDOO7l1Jl25ab5LePJZSdBQGdKHrkjY3UkkfNu3Cf--A4-pw4OPAYeyGQyElGnM_DwWWYAoBXIAxZ2zLUatcoTYbdpnSF0ApSwsXbCNEaQUHuWVQxW7oWhezz7XzdCyUsjDOWXQL5eOQaMnexn6izHeJXKIrdh5cTHR9yh37eHp8r57zw-v-pXo45JPgfMnRosKGIGgtwGngpBoFRMoJq3wbuPc6SGlJYCtQYwNKtiYgNsaXRy137O5vd5rH75XSUvddailGN9C4ppoDR7ACpDnS2xNdm558Pc1d7-af-v-l_AXl21Dr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1015092038</pqid></control><display><type>article</type><title>Clinical guidelines for late-onset Pompe disease</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Barba-Romero, M A ; Barrot, E ; Bautista-Lorite, J ; Gutierrez-Rivas, E ; Illa, I ; Jimenez, L M ; Ley-Martos, M ; Lopez de Munain, A ; Pardo, J ; Pascual-Pascual, S I ; Perez-Lopez, J ; Solera, J ; Vilchez-Padilla, J J</creator><creatorcontrib>Barba-Romero, M A ; Barrot, E ; Bautista-Lorite, J ; Gutierrez-Rivas, E ; Illa, I ; Jimenez, L M ; Ley-Martos, M ; Lopez de Munain, A ; Pardo, J ; Pascual-Pascual, S I ; Perez-Lopez, J ; Solera, J ; Vilchez-Padilla, J J</creatorcontrib><description>Before 2006, Pompe disease or glycogenosis storage disease type II was an incurable disease whose treatment was merely palliative. The development of a recombinant human alpha-glucosidase enzymatic replacement therapy has become the first specific treatment for this illness. The aim of this guide is to serve as reference for the management of the late-onset Pompe disease, the type of Pompe disease that develops after one year of age. In the guide a group of Spanish experts make specific recommendations about diagnosis, follow-up and treatment of this illness. With regard to diagnosis, the dried blood spots method is essential as the first step for the diagnosis of Pompe disease. The confirmation of the diagnosis of Pompe disease must be made by means of an study of enzymatic activity in isolated lymphocytes or a mutation analysis of the alpha-glucosidase gene. With regard to treatment with enzymatic replacement therapy, the experts say that is effective improving or stabilizating the motor function and the respiratory function and it must be introduced when the first symptoms attributable to Pompe disease appear.</description><identifier>EISSN: 1576-6578</identifier><identifier>DOI: 10.33588/rn.5408.2012088</identifier><identifier>PMID: 22492103</identifier><language>eng ; spa</language><publisher>Spain</publisher><subject>Algorithms ; Glycogen Storage Disease Type II - complications ; Glycogen Storage Disease Type II - diagnosis ; Glycogen Storage Disease Type II - therapy ; Humans</subject><ispartof>Revista de neurologiá, 2012-04, Vol.54 (8), p.497-507</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22492103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barba-Romero, M A</creatorcontrib><creatorcontrib>Barrot, E</creatorcontrib><creatorcontrib>Bautista-Lorite, J</creatorcontrib><creatorcontrib>Gutierrez-Rivas, E</creatorcontrib><creatorcontrib>Illa, I</creatorcontrib><creatorcontrib>Jimenez, L M</creatorcontrib><creatorcontrib>Ley-Martos, M</creatorcontrib><creatorcontrib>Lopez de Munain, A</creatorcontrib><creatorcontrib>Pardo, J</creatorcontrib><creatorcontrib>Pascual-Pascual, S I</creatorcontrib><creatorcontrib>Perez-Lopez, J</creatorcontrib><creatorcontrib>Solera, J</creatorcontrib><creatorcontrib>Vilchez-Padilla, J J</creatorcontrib><title>Clinical guidelines for late-onset Pompe disease</title><title>Revista de neurologiá</title><addtitle>Rev Neurol</addtitle><description>Before 2006, Pompe disease or glycogenosis storage disease type II was an incurable disease whose treatment was merely palliative. The development of a recombinant human alpha-glucosidase enzymatic replacement therapy has become the first specific treatment for this illness. The aim of this guide is to serve as reference for the management of the late-onset Pompe disease, the type of Pompe disease that develops after one year of age. In the guide a group of Spanish experts make specific recommendations about diagnosis, follow-up and treatment of this illness. With regard to diagnosis, the dried blood spots method is essential as the first step for the diagnosis of Pompe disease. The confirmation of the diagnosis of Pompe disease must be made by means of an study of enzymatic activity in isolated lymphocytes or a mutation analysis of the alpha-glucosidase gene. With regard to treatment with enzymatic replacement therapy, the experts say that is effective improving or stabilizating the motor function and the respiratory function and it must be introduced when the first symptoms attributable to Pompe disease appear.</description><subject>Algorithms</subject><subject>Glycogen Storage Disease Type II - complications</subject><subject>Glycogen Storage Disease Type II - diagnosis</subject><subject>Glycogen Storage Disease Type II - therapy</subject><subject>Humans</subject><issn>1576-6578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1z0tLxDAUBeAgiDOO7l1Jl25ab5LePJZSdBQGdKHrkjY3UkkfNu3Cf--A4-pw4OPAYeyGQyElGnM_DwWWYAoBXIAxZ2zLUatcoTYbdpnSF0ApSwsXbCNEaQUHuWVQxW7oWhezz7XzdCyUsjDOWXQL5eOQaMnexn6izHeJXKIrdh5cTHR9yh37eHp8r57zw-v-pXo45JPgfMnRosKGIGgtwGngpBoFRMoJq3wbuPc6SGlJYCtQYwNKtiYgNsaXRy137O5vd5rH75XSUvddailGN9C4ppoDR7ACpDnS2xNdm558Pc1d7-af-v-l_AXl21Dr</recordid><startdate>20120416</startdate><enddate>20120416</enddate><creator>Barba-Romero, M A</creator><creator>Barrot, E</creator><creator>Bautista-Lorite, J</creator><creator>Gutierrez-Rivas, E</creator><creator>Illa, I</creator><creator>Jimenez, L M</creator><creator>Ley-Martos, M</creator><creator>Lopez de Munain, A</creator><creator>Pardo, J</creator><creator>Pascual-Pascual, S I</creator><creator>Perez-Lopez, J</creator><creator>Solera, J</creator><creator>Vilchez-Padilla, J J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20120416</creationdate><title>Clinical guidelines for late-onset Pompe disease</title><author>Barba-Romero, M A ; Barrot, E ; Bautista-Lorite, J ; Gutierrez-Rivas, E ; Illa, I ; Jimenez, L M ; Ley-Martos, M ; Lopez de Munain, A ; Pardo, J ; Pascual-Pascual, S I ; Perez-Lopez, J ; Solera, J ; Vilchez-Padilla, J J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-59565be0f7720a701e6b60ee6a296dcf1dd7f339e25c2575b063c8f55b8d401e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2012</creationdate><topic>Algorithms</topic><topic>Glycogen Storage Disease Type II - complications</topic><topic>Glycogen Storage Disease Type II - diagnosis</topic><topic>Glycogen Storage Disease Type II - therapy</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barba-Romero, M A</creatorcontrib><creatorcontrib>Barrot, E</creatorcontrib><creatorcontrib>Bautista-Lorite, J</creatorcontrib><creatorcontrib>Gutierrez-Rivas, E</creatorcontrib><creatorcontrib>Illa, I</creatorcontrib><creatorcontrib>Jimenez, L M</creatorcontrib><creatorcontrib>Ley-Martos, M</creatorcontrib><creatorcontrib>Lopez de Munain, A</creatorcontrib><creatorcontrib>Pardo, J</creatorcontrib><creatorcontrib>Pascual-Pascual, S I</creatorcontrib><creatorcontrib>Perez-Lopez, J</creatorcontrib><creatorcontrib>Solera, J</creatorcontrib><creatorcontrib>Vilchez-Padilla, J J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Revista de neurologiá</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barba-Romero, M A</au><au>Barrot, E</au><au>Bautista-Lorite, J</au><au>Gutierrez-Rivas, E</au><au>Illa, I</au><au>Jimenez, L M</au><au>Ley-Martos, M</au><au>Lopez de Munain, A</au><au>Pardo, J</au><au>Pascual-Pascual, S I</au><au>Perez-Lopez, J</au><au>Solera, J</au><au>Vilchez-Padilla, J J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical guidelines for late-onset Pompe disease</atitle><jtitle>Revista de neurologiá</jtitle><addtitle>Rev Neurol</addtitle><date>2012-04-16</date><risdate>2012</risdate><volume>54</volume><issue>8</issue><spage>497</spage><epage>507</epage><pages>497-507</pages><eissn>1576-6578</eissn><abstract>Before 2006, Pompe disease or glycogenosis storage disease type II was an incurable disease whose treatment was merely palliative. The development of a recombinant human alpha-glucosidase enzymatic replacement therapy has become the first specific treatment for this illness. The aim of this guide is to serve as reference for the management of the late-onset Pompe disease, the type of Pompe disease that develops after one year of age. In the guide a group of Spanish experts make specific recommendations about diagnosis, follow-up and treatment of this illness. With regard to diagnosis, the dried blood spots method is essential as the first step for the diagnosis of Pompe disease. The confirmation of the diagnosis of Pompe disease must be made by means of an study of enzymatic activity in isolated lymphocytes or a mutation analysis of the alpha-glucosidase gene. With regard to treatment with enzymatic replacement therapy, the experts say that is effective improving or stabilizating the motor function and the respiratory function and it must be introduced when the first symptoms attributable to Pompe disease appear.</abstract><cop>Spain</cop><pmid>22492103</pmid><doi>10.33588/rn.5408.2012088</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 1576-6578
ispartof Revista de neurologiá, 2012-04, Vol.54 (8), p.497-507
issn 1576-6578
language eng ; spa
recordid cdi_proquest_miscellaneous_1015092038
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Algorithms
Glycogen Storage Disease Type II - complications
Glycogen Storage Disease Type II - diagnosis
Glycogen Storage Disease Type II - therapy
Humans
title Clinical guidelines for late-onset Pompe disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T18%3A03%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20guidelines%20for%20late-onset%20Pompe%20disease&rft.jtitle=Revista%20de%20neurologi%C3%A1&rft.au=Barba-Romero,%20M%20A&rft.date=2012-04-16&rft.volume=54&rft.issue=8&rft.spage=497&rft.epage=507&rft.pages=497-507&rft.eissn=1576-6578&rft_id=info:doi/10.33588/rn.5408.2012088&rft_dat=%3Cproquest_pubme%3E1015092038%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1015092038&rft_id=info:pmid/22492103&rfr_iscdi=true